REYON Pharmaceutical Past Earnings Performance
Past criteria checks 1/6
REYON Pharmaceutical has been growing earnings at an average annual rate of 27.4%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 4.9% per year. REYON Pharmaceutical's return on equity is 1.4%, and it has net margins of 2.4%.
Key information
27.4%
Earnings growth rate
25.9%
EPS growth rate
Pharmaceuticals Industry Growth | 11.3% |
Revenue growth rate | 4.9% |
Return on equity | 1.4% |
Net Margin | 2.4% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
There May Be Reason For Hope In REYON Pharmaceutical's (KRX:102460) Disappointing Earnings
Mar 31Consider This Before Buying REYON Pharmaceutical Co., Ltd. (KRX:102460) For The 1.6% Dividend
May 08Here's Why REYON Pharmaceutical (KRX:102460) Has A Meaningful Debt Burden
Apr 09What Percentage Of REYON Pharmaceutical Co., Ltd. (KRX:102460) Shares Do Insiders Own?
Feb 28Read This Before Buying REYON Pharmaceutical Co., Ltd. (KRX:102460) For Its Dividend
Jan 20REYON Pharmaceutical (KRX:102460) Seems To Use Debt Quite Sensibly
Jan 02Did REYON Pharmaceutical's (KRX:102460) Share Price Deserve to Gain 50%?
Dec 12How Much Of REYON Pharmaceutical Co., Ltd. (KRX:102460) Do Insiders Own?
Nov 24Revenue & Expenses BreakdownBeta
How REYON Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 151,071 | 3,583 | 64,243 | 8,375 |
30 Sep 23 | 150,584 | 8,456 | 64,489 | 10,363 |
30 Jun 23 | 152,043 | 10,614 | 64,326 | 9,826 |
31 Mar 23 | 153,907 | 7,484 | 65,732 | 8,274 |
31 Dec 22 | 154,039 | 7,434 | 66,206 | 6,705 |
30 Sep 22 | 152,549 | 4,816 | 66,936 | 5,410 |
30 Jun 22 | 150,237 | 2,774 | 66,442 | 7,878 |
31 Mar 22 | 146,329 | 6,265 | 64,215 | 9,161 |
31 Dec 21 | 142,801 | 5,412 | 63,619 | 9,725 |
30 Sep 21 | 139,414 | 5,650 | 62,114 | 10,372 |
30 Jun 21 | 135,893 | 6,518 | 62,025 | 7,890 |
31 Mar 21 | 131,303 | 4,843 | 59,641 | 6,508 |
31 Dec 20 | 130,034 | 3,844 | 59,765 | 6,584 |
30 Sep 20 | 129,738 | 1,720 | 61,276 | 5,255 |
30 Jun 20 | 129,684 | 2,165 | 61,685 | 4,370 |
31 Mar 20 | 131,581 | 2,165 | 62,820 | 3,587 |
31 Dec 19 | 131,558 | 4,946 | 59,876 | 3,724 |
30 Sep 19 | 128,267 | 1,478 | 60,754 | 4,580 |
30 Jun 19 | 125,963 | 594 | 60,335 | 4,580 |
31 Mar 19 | 124,192 | 3,299 | 60,584 | 5,045 |
31 Dec 18 | 122,990 | 1,343 | 57,424 | 6,697 |
30 Sep 18 | 122,850 | 7,021 | 53,081 | 5,857 |
30 Jun 18 | 123,936 | 9,643 | 52,213 | 5,857 |
31 Mar 18 | 124,150 | 9,073 | 48,510 | 6,132 |
31 Dec 17 | 126,253 | 12,887 | 51,340 | 3,454 |
30 Sep 17 | 126,748 | 13,195 | 51,297 | 4,522 |
31 Dec 16 | 121,847 | 10,701 | 48,496 | 6,495 |
30 Sep 13 | 110,061 | 12,379 | 46,163 | 0 |
30 Jun 13 | 113,143 | 13,408 | 47,173 | 0 |
Quality Earnings: A102460 has a large one-off loss of ₩2.5B impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: A102460's current net profit margins (2.4%) are lower than last year (4.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A102460's earnings have grown significantly by 27.4% per year over the past 5 years.
Accelerating Growth: A102460's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A102460 had negative earnings growth (-51.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (36.1%).
Return on Equity
High ROE: A102460's Return on Equity (1.4%) is considered low.